Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019)

ENDRA Life Sciences (NDRA) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $249256.0 as the latest value for Q4 2019.

  • Quarterly Asset Writedowns and Impairment rose 186.69% to $249256.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $249256.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $249256.0 for FY2019, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2019 was $249256.0 at ENDRA Life Sciences, up from -$287541.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $287541.0 in Q3 2018, with the low at -$287541.0 in Q4 2018.